Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer

• Published in: Translational research : the journal of laboratory and clinical medicine Vol. 212; pp. 89 - 103
• Main Authors: Jiménez-Vacas, Juan M., Herrero-Aguayo, Vicente, Gómez-Gómez, Enrique, León-González, Antonio J., Sáez-Martínez, Prudencio, Alors-Pérez, Emilia, Fuentes-Fayos, Antonio C., Martínez-López, Ana, Sánchez-Sánchez, Rafael, González-Serrano, Teresa, López-Ruiz, Daniel J., Requena-Tapia, María J., Castaño, Justo P., Gahete, Manuel D., Luque, Raúl M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2019
• Subjects: Aged; Antineoplastic Agents - pharmacology; Biomarkers, Tumor - blood; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Phosphoproteins - genetics; Phosphoproteins - metabolism; Prognosis; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; RNA Splicing Factors - genetics; RNA Splicing Factors - metabolism; Spliceosomes - chemistry; NMD; IHC; N-TAR; ISUP; EMT; TCGA; PCa; STR; SURF; SF; FFPE; PIRADS; CRPC; cSCC; snRNP; EJC; PSA
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2019.07.001

Prostate cancer (PCa) is one of the most common cancers types among men. Development and progression of PCa is associated with aberrant expression of oncogenic splicing-variants (eg, AR-v7), suggesting that dysregulation of the splicing process might represent a potential actionable target for PCa. Expression levels (mRNA and protein) of SF3B1, one of the main components of the splicing machinery, were analyzed in different cohorts of PCa patients (clinically localized [n = 84], highly aggressive PCa [n = 42], and TCGA dataset [n = 497]). Functional and mechanistic assays were performed in response to pladienolide-B in nontumor and tumor-derived prostate cells. Our results revealed that SF3B1 was overexpressed in PCa tissues and its levels were associated with clinically relevant PCa-aggressive features (eg, metastasis/AR-v7 expression). Moreover, inhibition of SF3B1 activity by pladienolide-B reduced functional parameters of aggressiveness (proliferation/migration/tumorspheres-formation/apoptosis) in PCa cell lines, irrespective of AR-v7 expression, and reduced viability of primary PCa cells. Antitumor actions of pladienolide-B involved: (1) inhibition of PI3K/AKT and JNK signaling pathways, (2) modulation of tumor markers and splicing variants (AR-v7/In1-ghrelin), and (3) regulation of key components of mRNA homeostasis-associated machineries (spliceosome/SURF/EJC). Altogether, our results demonstrated that SF3B1 is overexpressed and associated with malignant features in PCa, and its inhibition reduces PCa aggressiveness, suggesting that SF3B1 could represent a novel prognostic biomarker and a therapeutic target in PCa.